Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

6.6K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
6.6K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).

Transfusion medicine (Oxford, England)·2019
Same author

Donor medicine: giving it all.

Transfusion medicine (Oxford, England)·2019
Same author

Six-month outcomes after restrictive or liberal transfusion for cardiac surgery (TRICS III trial).

Transfusion medicine (Oxford, England)·2019
Same author

Platelet transfusion thresholds in premature neonates (PlaNeT-2 trial).

Transfusion medicine (Oxford, England)·2019
Same author

Patient blood management - a renaissance of transfusion medicine.

Transfusion medicine (Oxford, England)·2018
Same author

A multicentred study to validate a consensus bleeding assessment tool developed by the biomedical excellence for safer transfusion collaborative for use in patients with haematological malignancy.

Vox sanguinis·2018

Related Experiment Video

Updated: Apr 21, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Why has demand for platelet components increased? A review.

L J Estcourt1

  • 1NHS Blood and Transplant, Oxford, UK; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Transfusion Medicine (Oxford, England)
|October 21, 2014
PubMed
Summary

Demand for platelet transfusions is rising, particularly for patients with blood cancers. While population growth is a factor, other reasons for increased use in cardiac surgery and intensive care patients require further investigation due to sparse data.

Keywords:
blood supplyplateletstransfusion

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

16.3K
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

9.1K

Related Experiment Videos

Last Updated: Apr 21, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

16.3K
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

9.1K

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Critical Care

Background:

  • Platelet transfusions are crucial for managing bleeding in patients with low platelet counts or dysfunction.
  • There has been a notable increase in the demand for platelet components globally.
  • Key patient groups utilizing platelet components include those with hematological malignancies, cardiac surgery patients, and intensive care unit (ICU) patients.

Purpose of the Study:

  • To explore factors contributing to the rising demand for platelet components in specific patient populations.
  • To analyze trends in platelet component usage among patients with hematological malignancies, undergoing cardiac surgery, and in intensive care.

Main Methods:

  • Review of existing literature and data on platelet transfusion usage.
  • Analysis of demographic and clinical factors potentially influencing platelet component demand.
  • Correlation of available data with national component usage statistics.

Main Results:

  • Patients with hematological malignancies represent the largest group of platelet component users (up to 67%).
  • Increased population size is the only factor directly correlating with national component data.
  • Evidence for increased platelet component use in cardiac surgery or ICU patients beyond general population trends is limited and data are sparse.

Conclusions:

  • Rising demand for platelet transfusions is linked to an aging population, increased incidence of hematological malignancies, and evolving treatment strategies.
  • Further research with more comprehensive data is needed to fully understand the drivers of increased platelet component use in cardiac surgery and intensive care settings.